Skip to main content
Premium Trial:

Request an Annual Quote

Pacific Biometrics' Q1 Revenues Rise 27 Percent

NEW YORK (GenomeWeb News) – Pacific Biometrics today reported that its first-quarter 2010 revenues increased 27 percent, though it also noted that it did not meet its internal revenues goal.

The Seattle-based clinical lab and biomarker assay services firm brought in total revenues of $2.3 million for the three-month period ended Sept. 30, compared to revenues of $1.8 million for the first quarter of 2009.

Ron Helm, chairman and CEO of Pacific Biometrics noted that the firm did not reach its internal revenue goal, "in part because of the early termination of several clinical studies for reasons unrelated to our performance.

"We also cannot ignore the ongoing economic difficulties that continue to impact the clinical trials industry, combined with the impact of tight credit markets on spending and investment in all sectors of our markets," he added.

Pacific Biometrics' net loss for the quarter was $273,150, or $.01 per share, up from a net loss of $5,737, or $.00 per share, for the first quarter of 2009. The firm said that the increase in net loss was due to its reporting in Q1 2009 of a significant non-cash gain related to convertible debt that was outstanding.

The company finished the quarter with $3.2 million in cash and cash equivalents.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more